Amanita muscaria – poisonous, or are we missing part of the picture?

Amanita muscaria, the red fly agaric, is often simply described as poisonous. That is not wrong – the mushroom contains, among other things, ibotenic acid and muscimol, and greater exposure can cause clear poisoning.

But the question is whether the scientific picture is sometimes oversimplified.

A large part of the argument about the neurotoxicity of ibotenic acid comes from animal experiments where the substance is used to intentionally create brain lesions. In several such studies, ibotenic acid is injected directly into specific parts of the brain.

This clearly shows that ibotenic acid can be excitotoxic to nerve cells.

But that is not the same as showing that small amounts taken orally cause corresponding neurological damage.

Route of administration, local concentration, metabolism, and exposure differ greatly

.

Why do some question the conclusion?

It is precisely this difference that has made many research-interested users critical of how these studies are sometimes presented online.

On forums like Reddit and in user communities, the criticism recurs with the question:

Is direct injection of ibotenic acid into brain tissue a realistic model for normal oral exposure?

That does not mean that ibotenic acid is harmless.

It means that the question: "Is ibotenic acid neurotoxic?" and the question: "Does low oral exposure to Amanita muscaria cause neurodegeneration in humans?" are not the same scientific question.

There is still very little good research on the latter.

 

At the same time, users report positive effects

There is also a growing number of anecdotal reports from people who use small amounts of Amanita muscaria.

Common experiences include improved sleep, less anxiety and mental restlessness, increased calm, altered or clearer dreams, as well as improved subjective well-being, among others.

There are also negative reports including nausea, brain fog, anxiety, and sleep problems, which are also said to indicate higher levels of ibotenic acid relative to muscimol.

Therefore, user stories should not be considered clinical evidence.

But when many people independently report similar effects, at least a legitimate research question arises.

 

Muscimol makes the question even more interesting

Muscimol is a potent agonist at GABA-A receptors – one of the brain's most important inhibitory signaling systems.

This provides a biologically plausible explanation for why some users report, for example, sedation, calm, and altered sleep.

But biological plausibility is still not the same as clinically proven effect.

 

Is Amanita muscaria the next psilocybin?

We do not know.

Psilocybin is a good example of how a long-stigmatized substance later showed therapeutic potential when it was studied in controlled clinical trials.

That does not mean that Amanita muscaria will show the same.

But it shows why the question should be decided through good research, not solely through historical stigma or user anecdotes.

 

Conclusion

Amanita muscaria is neither something that should be described as completely risk-free nor automatically dismissed as a meaningless poison.

We know that the mushroom can cause acute poisoning and that ibotenic acid has excitotoxic properties when large amounts are ingested and when the mushroom has not undergone drying.

But we still lack good human studies that answer the questions many are really interested in:

What happens with low oral exposure? Are there reproducible positive effects? What do the risks look like over time?

The most reasonable answer today is therefore perhaps not that Amanita muscaria is safe – or dangerous in all contexts.

It is that we still know too little, but at the same time more than ever before.